{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:02:21Z","timestamp":1787169741595,"version":"build-2736575974"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Chronic bullous disease of childhood is a rare subepidermal bullous disease with a hallmark of linear IgA deposition along basement membrane zone seen on direct immunofluorescence. We report a case of a 2-year-old male child, who had recurrent and multiple bullous eruptions over body and he was not responding to conventional therapy. He had earlier developed a drug reaction to dapsone which is considered the drug of choice for this condition. We report successful management of this case with injection rituximab which is a chimeric monoclonal antibody against CD20, which is primarily found on the surface of B cells.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/idoj.idoj_223_21","type":"journal-article","created":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T00:02:05Z","timestamp":1646265725000},"page":"248-251","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Successful Treatment of Refractory Chronic Bullous Disease of Childhood with Rituximab"],"prefix":"10.4103","volume":"13","author":[{"given":"Debdeep","family":"Mitra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuj","family":"Bhatnagar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautam K.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunmeet","family":"Sandhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-13-20240828","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1365-4362.1993.tb01441.x","article-title":"Chronic bullous dermatoses in China","volume":"32","author":"Jin","year":"1993","journal-title":"Int J Dermatol"},{"key":"R2-13-20240828","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1525-1470.1988.tb00896.x","article-title":"Chronic bullous dermatosis of childhood persisting into adulthood","volume":"5","author":"Burge","year":"1988","journal-title":"Pediatr Dermatol"},{"key":"R3-13-20240828","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1136\/pmj.79.934.437","article-title":"Chronic bullous dermatosis of childhood","volume":"79","author":"Thappa","year":"2003","journal-title":"Postgrad Med J"},{"key":"R4-13-20240828","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1080\/000155599750010229","article-title":"IgA antibodies recognizing LABD97 are predominantly IgA1 subclass","volume":"79","author":"Egan","year":"1999","journal-title":"Acta Derm Venereol"},{"key":"R5-13-20240828","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1365-2133.1994.tb08491.x","article-title":"Chronic bullous disease of childhood and linear IgA disease of adults are IgA1-mediated diseases","volume":"131","author":"Wojnarowska","year":"1994","journal-title":"Br J Dermatol"},{"key":"R6-13-20240828","first-page":"128","article-title":"Juvenile dermatitis herpetiformis","volume":"54","author":"Grant","year":"1968","journal-title":"Trans St Johns Hosp Dermatol Soc"},{"key":"R7-13-20240828","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1001\/archderm.1961.01580120007002","article-title":"Dermatitis herpetiformis in children.Relationship to bullous pemphigoid","volume":"83","author":"Kim","year":"1961","journal-title":"Arch Dermatol"},{"key":"R8-13-20240828","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1001\/archderm.1970.04000060001001","article-title":"Childhood bullous dermatitis herpetiformis.Negative immunofluorescent tests","volume":"101","author":"Jordon","year":"1970","journal-title":"Arch Dermatol"},{"key":"R9-13-20240828","first-page":"58","article-title":"Chronic bullous disease of childhood","volume":"7","author":"Wojnarowska","year":"1988","journal-title":"Semin Dermatol"},{"key":"R10-13-20240828","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/j.1365-2230.1991.tb00336.x","article-title":"Chronic bullous dermatosis of childhood--clinical and immunological features seen in African patients","volume":"16","author":"Aboobaker","year":"1991","journal-title":"Clin Exp Dermatol"},{"key":"R11-13-20240828","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/S0190-9622(88)70236-4","article-title":"Chronic bullous disease of childhood, childhood cicatricial pemphigoid, and linear IgA disease of adults.A comparative study demonstrating clinical and immunopathologic overlap","volume":"19","author":"Wojnarowska","year":"1988","journal-title":"J Am Acad Dermatol"},{"key":"R12-13-20240828","first-page":"43","article-title":"Linear IgA bullous dermatosis: A rare clinicopathologic entity with an unusual presentation","volume":"8","author":"Chaudhari","year":"2015","journal-title":"J Clin Aesthet Dermatol"},{"key":"R13-13-20240828","doi-asserted-by":"crossref","first-page":"6716","DOI":"10.4103\/0378-6323.102354","article-title":"Rituximab in pemphigus","volume":"78","author":"Kanwar","year":"2012","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"R14-13-20240828","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1001\/jamadermatol.2015.59","article-title":"Persistence of autoreactive IgA-Secreting B cells despite multiple immunosuppressive medications including rituximab","volume":"151","author":"He","year":"2015","journal-title":"JAMA Dermatol"},{"key":"R15-13-20240828","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jdcr.2018.11.004","article-title":"Linear IgA bullous dermatosis treated with rituximab","volume":"5","author":"Pinard","year":"2019","journal-title":"JAAD Case Rep"},{"key":"R16-13-20240828","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s10157-016-1313-5","article-title":"Rituximab for nephrotic syndrome in children","volume":"21","author":"Iijima","year":"2017","journal-title":"Clin Exp Nephrol"},{"key":"R17-13-20240828","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1517\/14740338.4.3.599","article-title":"Reactivation of hepatitis B virus with rituximab","volume":"4","author":"Tsutsumi","year":"2005","journal-title":"Expert Opin Drug Saf"},{"key":"R18-13-20240828","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jaut.2007.11.013","article-title":"The emergence of progressive multifocal leukoencephalopathy (PML) in rheumatic diseases","volume":"30","author":"Boren","year":"2008","journal-title":"J Autoimmun"}],"container-title":["Indian Dermatology Online Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/idoj.idoj_223_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:11:30Z","timestamp":1787166690000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/idoj.idoj_223_21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/idoj.idoj_223_21","relation":{},"ISSN":["2229-5178"],"issn-type":[{"value":"2229-5178","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]}}}